Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.

John Higgins Biography and Net Worth

Director of Bio-Techne

John L. Higgins has served on the Company's Board since 2009. Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals, Inc. since January 2007 and has been a member of Ligand's Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006. Mr. Higgins was previously a member of the executive management team and a director at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Mr. Higgins also serves as Chairman of CoMentis, Inc., a biopharmaceutical company, and has served as a director of numerous public and private companies.

What is John L. Higgins' net worth?: The estimated net worth of John L. Higgins is at least $179.14 million as of May 23rd, 2023. Mr. Higgins owns 2,462,686 shares of Bio-Techne stock worth more than $179,135,780 as of December 23rd. This net worth estimate does not reflect any other assets that Mr. Higgins may own. Learn More about John L. Higgins' net worth.
How do I contact John L. Higgins?: The corporate mailing address for Mr. Higgins and other Bio-Techne executives is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. Bio-Techne can also be reached via phone at (612) 379-8854 and via email at [email protected]. Learn More on John L. Higgins' contact information.
Has John L. Higgins been buying or selling shares of Bio-Techne?: John L. Higgins has not been actively trading shares of Bio-Techne during the past quarter. Most recently, John L. Higgins sold 1,992 shares of the business's stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $377.11, for a transaction totalling $751,203.12. Following the completion of the sale, the director now directly owns 6,014 shares of the company's stock, valued at $2,267,939.54. Learn More on John L. Higgins' trading history.
Who are Bio-Techne's active insiders?: Bio-Techne's insider roster includes Robert Baumgartner (Director), Norman Eansor (Insider), Brenda Furlow (SVP), John Higgins (Director), James Hippel (CFO), Kim Kelderman (CEO, President & Director), Charles Kummeth (CEO), Roeland Nusse (Director), and Alpna Seth (Director). Learn More on Bio-Techne's active insiders.
Are insiders buying or selling shares of Bio-Techne?: In the last twelve months, insiders at the biotechnology company sold shares 1 times. They sold a total of 10,400 shares worth more than $800,592.00. The most recent insider tranaction occured on March, 7th when Director Roeland Nusse sold 10,400 shares worth more than $800,592.00. Insiders at Bio-Techne own 3.9% of the company. Learn More about insider trades at Bio-Techne.
Information on this page was last updated on 3/7/2024.

John L. Higgins Insider Trading History at Bio-Techne

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/10/2022	Sell	1,992	$377.11	$751,203.12	6,014
6/7/2022	Sell	1,000	$364.31	$364,310.00	4,606
6/4/2019	Sell	5,000	$203.67	$1,018,350.00	8,526
8/23/2018	Sell	10,000	$187.92	$1,879,200.00	13,012
9/8/2016	Sell	1,700	$109.83	$186,711.00	1,359

John L. Higgins Buying and Selling Activity at Bio-Techne

Bio-Techne Company Overview

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Today's Range

Now: $72.74

$71.27

$73.13

50 Day Range

MA: $73.31

$66.37

$77.62

2 Week Range

Now: $72.74

$61.16

$85.57

Volume

618,835 shs

Average Volume

1,009,151 shs

Market Capitalization

$11.56 billion

P/E Ratio

77.38

Dividend Yield

0.44%

Beta

1.27

Has Trump Finally Gone Too Far?

From Insiders Exposed | Ad